Aescap 2.0 is an open-end biotech fund for join account (a typical Dutch FGR structure) that exclusively invests in the shares of publicly traded biotech / life sciences companies. It invests in high-growth, highly innovative companies that develop and market new medicines and, to a lesser extent, diagnostics and/or medical devices. Entry into and exit from this biotech fund is possible twice per month.
The biotech market is a large and fast-growing market where breakthrough medicines can be sold globally. The substantial growth of the biotech market, also called life sciences market, is driven by a longer life expectancy (especially in the emerging markets) as well as an ageing population. Both factors are driving demand for improved and cost-effective medicine, diagnostics and medical devices. There is also still a high unmet medical need for diseases like Alzheimer’s, Arthritis, Cancer, Diabetes, Multiple Sclerosis (MS), Obesity, Parkinson’s and many other diseases. Today for approximately 6,000 rare diseases there is still no cure or treatment at all available.
Aescap 2.0 was founded by portfolio manager Patrick Krol on March 28th 2016. The fund has a focused portfolio, investing in approximately 18 companies. Within this focus it will ensure that the portfolio is diversified over many different diseases and geographic areas. The fund’s objective is to make an annual net return (after deduction of costs) of 20% over the mid-term (4-5 years). The name Aescap is derived from Aesculapius, the Roman god of Medicine, and “Capital”. The first fund named Aescap was Aescap 1, a venture capital fund founded by Dinko Valerio, Michiel de Haan and Patrick Krol, investing in private biotech / life science companies.
The Portfolio Manager of Aescap 2.0 is Patrick Krol. He developed an highly disciplined investment strategy based on his own experience investing in public biotech companies over more than 30 years, during which he went through several stock market cycles. He believes the fund’s buy/sell discipline and risk management is key to its success. Also, he does not shy away from being an activist investor where necessary. Mr. Krol’s strategy has resulted in an outstanding performance that has granted Aescap 2.0 a 5-star Morningstar rating (the highest rating available) and has generated an exceptional annualized return to investors in the fund, see the ‘Performance’ page.
Aescap 2.0 is managed by Privium Fund Management B.V. (Privium) as Alternative Investment Fund Manager of the fund. The Fund Manager is responsible for the entire management of the fund in accordance with the provisions of the Fund Documents and applicable laws. Privium Fund Management B.V. is authorized and regulated by the Dutch Authority for the Financial Markets (www.afm.nl) as an Alternative Investment Fund Manager (AIFM) as referred to in article 2:65 (a). Both Privium and the fund are registered in the Register of AFM. Privium is an Asset Manager with offices in Amsterdam, London and Hong Kong and focuses on alternative investments. As a group, Privium is managing over USD 2.3 billion. For additional information on the Fund Manager please visit Privium’s website at: www.priviumfund.com.